Actimed Therapeutics, a London, UK-based clinical stage pharmaceutical company, closed its second and final £5M tranche of Seed financing.
The closing of this round, led by Mankind Pharma, brings the total seed funding raised by Actimed to approximately £10M. Following this financing, Atish Majumdar, President (Sales & Marketing) of Mankind Pharma joined Actimed Therapeutics as a member of its Board of Directors.
The company intends to use the funds to support the development of its portfolio, including preparation for the Phase 2b/3 programme for its lead asset, S-pindolol benzoate, being developed for the treatment of cancer cachexia.
Founded in 2017 by Stefan Anker, Andrew Coats, and Yann Colardelle, and led by CEO Robin Bhattacherjee, Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. Its lead product, S-pindolol benzoate (ACM-001.1) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients. Actimed is currently preparing for further phase 2b/3 clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).
FinSMEs
05/01/2023